Elena Zamagni MD, PhD

Board Member

Elena Zamagni MD, PhD, is an Associate Professor of Hematology at the Bologna University, Italy since January 2021. She received her medical degree from University of Bologna, where she also served her residency in haematology. She got PHD in Clinical Hematology at the University of Bologna in May 2005. She qualified for the position of full professor in 2018. She is a lecturer in several courses at the Bologna University School of Medicine and has mentored several students in their career.

She has been responsible for the Program of management and treatment of monoclonal gammopathies and multiple myeloma since 2013.

Her research interests include areas related to multiple myeloma, in particular on the role of high dose therapy with stem cell support, of prognostic factors, minimal residual disease and of imaging techniques.

In the field of imaging, she has contributed to the following achievements:

  • Demonstration of the prognostic role of PET/CT (2011)
  • Definition of the imaging-MRD category (2016)
  • Reccomendations on imaging algorithm in plasma cell dyscrasia (2019)
  • Standardization of the use of PET/CT in MM (2021)
  • Definition of EMD (2022)
  • Consensus on the use of molecular imaging in MM within the European Association of Nuclear Medicine (2023)

She has published over 160 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia (IF total 2596, 490; H index global 56; citation index 16.591). She has contributed to the educational session of the Italian Society of Haematology (SIE) and American Society of Clinical Oncology (ASCO). She is abstracts reviewer for SIE, EHA and ASH. She is part of the editorial board of several haematological journals with high IF (JCO, Blood Cancer Journal, Leukemia). She is an active member of the board of the GIMEMA and European Myeloma Network (EMN) working party and she has cooperated in the Scientific secretary and as principal investigator in several national and international randomized trials in multiple myeloma. She is a member of the Italian Society of Haematology, the International Myeloma Working Group and the International Myeloma Society. She has served on the EHA’s Scientific Program Committee from 2017 to 2021 and she is currently serving for ESMO. She has served as co-chair of the Career Development Committee within the International Myeloma Society since 2019.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events